NOBIVAC® PUPPY DP

NOBIVAC® PUPPY DP
Reg. No. G2323 (Act 36/1947)
Namibia Reg. No. V97/24.1/888 NS0

NOBIVAC® PUPPY DP
Reg. No. G2323 (Act 36/1947)
Namibia Reg. No. V97/24.1/888 NS0

FOR ANIMAL USE ONLY

This vaccine may only be used by or under the supervision of persons registered in terms of or authorised in terms of section 23 (1) (c) of the Veterinary and Para-veterinary Professions Act, 1982 (Act No. 19 of 1982).

INDICATIONS
For the active immunisation of young puppies against canine distemper and canine parvovirus disease.

COMPOSITION
Each vial contains canine distemper virus, strain Onderstepoort ≥ 105 TCID50 and canine parvovirus, strain 154 ≥ 107 TCID50.
It is a combination of live attenuated strains of canine distemper virus and canine parvovirus grown in cell-line tissue culture and presented as a freeze-dried plug.
Each vial contains a single dose for reconstitution.

TARGET SPECIES
Dogs

STORAGE

  • Store in a dark place between 2 °C and 8 °C.
  • Do not freeze.
  • Avoid prolonged or repetitive exposure to high ambient temperatures.
  • Allow the vaccine to gradually reach room temperature (20 °C to 25 °C) prior to use.
  • Protect from direct sunlight.
  • The diluent may be stored at room temperature.

WARNINGS

  • Do not open and reconstitute the vaccine until ready to start the vaccination.
  • The vaccine should be reconstituted using Nobivac® Diluent immediately prior to use.
  • Do not store partially used containers for future use and use the entire contents when opened.
  • As with all vaccines, anaphylactic or hypersensitivity reactions may occur.
  • Accidental self-injection may lead to severe allergic reactions. Consult a physician.
  • Destroy any unused, reconstituted vaccine, empty vaccine containers, needles, etc. according to local waste disposal regulations, after completion of the vaccination.
  • KEEP OUT OF REACH OF CHILDREN, UNINFORMED PERSONS AND ANIMALS.
  • Although this remedy has been extensively tested under a large variety of conditions, failure thereof may ensue as a result of a wide range of reasons. If this is suspected, seek veterinary advice and notify the registration holder.

PRECAUTIONS

  • Only healthy puppies should be vaccinated, and an adequate clinical examination should be made prior to inoculation.
  • Observe aseptic precautions. Ensure that vaccination equipment (needles, syringes, etc.) are clean and sterile prior to use.
  • Avoid intravenous injection.
  • Hypersensitivity reactions, following administration are rare but as with all vaccines it may occasionally be encountered. In this event administration of adrenaline injection by the subcutaneous route may be indicated.
  • Avoid contamination of the vaccine with traces of disinfectant and spirits.
  • It is good vaccination practice when handling the vaccine to avoid contact with the eyes, hands and clothing.

DIRECTIONS FOR USE – USE ONLY AS DIRECTED

  • Puppies should be vaccinated with a single dose of Nobivac® Puppy DP at 4 to 6 weeks of age, preferably before weaning.
  • Puppies which have received Nobivac® Puppy DP should be further immunised with Nobivac® DHPPi, 3 to 4 weeks later.

DOSAGE AND ADMINISTRATION
The contents of 1 vial of reconstituted vaccine should be injected subcutaneously.
Reconstitute immediately prior to use by the addition of the contents of 1 vial (1,0 mℓ) of Nobivac® Diluent. The vaccine should be administered by subcutaneous injection in the neck or chest region, observing the usual aseptic precautions.

PRESENTATION
Polyethylene terephthalate (PET) tray containing 10 single dose vials of freeze-dried vaccine.

REGISTRATION HOLDER                                            MANUFACTURER
Intervet South Africa (Pty) Ltd.                                    Intervet International B.V.
20 Spartan Road, Spartan                                              35 Wim de Körver Straat
1619, RSA                                                             Boxmeer, The Netherlands
Tel: +27 (0) 11 923 9300
Fax: +27 (0) 11 392 3158
www.msd-animal-health.co.za

DATE OF PUBLICATION OF THIS PACKAGE INSERT

 20 August 2013

Zimbabwe Reg. No. E97/80.23.15/9465
Pharmaceutical Classification: 802315
Distribution Category: V.M.G.D